Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2021 14:40 ET | Source: AB Science

AB Science reçoit l’autorisation de la FDA de reprendre le recrutement des patients dans l'étude confirmatoire de phase 3 du masitinib (AB19001) chez les patients atteints de SLA

COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT L'AUTORISATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE DE REPRENDRE LE RECRUTEMENT DE PATIENTS DANS L'ÉTUDE DE PHASE 3 DU MASITINIB DANS LA...
November 18, 2021 14:40 ET | Source: AB Science

AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS

PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO RESUME PATIENT ENROLMENT IN THE PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) ...
November 18, 2021 10:56 ET | Source: MUMO Studio

MUMO Studio Launches a Campaign for DUBIUM, a Survival Thriller Game

CYPRESS, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- MUMO Studio has launched a Kickstarter campaign today to support the development and help build a community around their debut title, DUBIUM. This...
September 02, 2021 11:59 ET | Source: AB Science

AB Science annonce aujourd’hui que les dernières données cliniques de survie à long terme dans la SLA seront présentées au colloque international 2021 de la SLA et des maladies du motoneurone

COMMUNIQUE DE PRESSE AB SCIENCE PRESENTERA LES DERNIERES DONNEES CLINIQUES DE SURVIE A LONG TERME DANS LA SCLEROSE LATERALE AMYOTROPHIQUE AU COLLOQUE INTERNATIONAL 2021 DE LA SCLEROSE LATERALE...
September 02, 2021 11:59 ET | Source: AB Science

AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND

PRESS RELEASE AB SCIENCE TO PRESENT LATEST CLINICAL DATA ON LONG-TERM SURVIVAL ANALYSES IN AMYOTROPHIC LATERAL SCLEROSIS AT THE 2021 INTERNATIONAL SYMPOSIUM ON ALS/MND Paris, 2 September, 2021, 6pm...
July 28, 2021 10:56 ET | Source: Green Builder Media

Resilient Housing Is Needed More Than Ever: But Is It Too Late?

Lake City, Colo., July 28, 2021 (GLOBE NEWSWIRE) -- Join Green Builder Media on August 3 at 2:00 pm EDT for the next in its housing-related webinar series: “Why Building and Designing Homes With...
July 19, 2021 12:12 ET | Source: AB Science

AB Science annonce la publication de nouvelles données de survie montrant que le masitinib prolongeait la survie dans la SLA de 25 mois par rapport au placebo

COMMUNIQUE DE PRESSE DE NOUVELLES DONNEES À LONG TERME SUR UNE DUREE DE 75 MOIS ONT MONTRÉ QUE LE MASITINIB PROLONGEAIT LA SURVIE DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE DE 25 MOIS PAR RAPPORT AU...
July 19, 2021 12:12 ET | Source: AB Science

AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo

PRESS RELEASE LONG-TERM FOLLOW-UP OF 75 MONTHS SHOWED THAT MASITINIB EXTENDED SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS BY 25 MONTHS RELATIVE TO PLACEBO, PROVIDED THAT TREATMENT STARTS EARLY...
November 27, 2020 00:00 ET | Source: Archway Publishing

‘Jeremy Longtail and the Hunt for Mongolia’ is more than a simple animal tale

ELLICOTT CITY, Md., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Jeremy Longtail, a gerbil, is determined to find Mongolia, the native home of his ancestors. Readers can follow him as he travels the wild road...
November 24, 2020 15:16 ET | Source: Modus Research Inc.

Modus Research: Canadian Businesses Are Much More Optimistic About Long-Term Survival Than in the Spring

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The latest findings from The Business Monitor, which surveyed of over 1,000 Canadian managers and executives, show a big upswing in business leaders’...